We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Unicorn Aim Vct Plc | LSE:UAV | London | Ordinary Share | GB00B1RTFN43 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 91.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 88.00 | 95.00 | 91.50 | 91.50 | 91.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investors, Nec | -5.67M | -10.59M | -0.0612 | -14.95 | 158.18M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 91.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 08/4/2024 | 13:46 | UK RNS | Unicorn AIM VCT PLC Net Asset Value(s) |
| 02/4/2024 | 10:46 | UK RNS | Unicorn AIM VCT PLC Total Voting Rights |
| 18/3/2024 | 07:00 | UK RNS | Unicorn AIM VCT PLC Transaction in Own Shares |
| 11/3/2024 | 12:00 | UK RNS | Unicorn AIM VCT PLC Director/PDMR Shareholding |
| 11/3/2024 | 11:59 | UK RNS | Unicorn AIM VCT PLC Total Voting Rights |
| 11/3/2024 | 11:57 | UK RNS | Unicorn AIM VCT PLC Issue of Equity |
| 07/3/2024 | 11:34 | UK RNS | Unicorn AIM VCT PLC Net Asset Value(s) |
| 01/3/2024 | 10:54 | UK RNS | Unicorn AIM VCT PLC Total Voting Rights |
| 15/2/2024 | 16:30 | UK RNS | Unicorn AIM VCT PLC Offer for Subscription Update |
| 14/2/2024 | 13:36 | UK RNS | Unicorn AIM VCT PLC Director/PDMR Shareholding |
Unicorn Aim Vct (UAV) Share Charts1 Year Unicorn Aim Vct Chart |
|
1 Month Unicorn Aim Vct Chart |
Intraday Unicorn Aim Vct Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/3/2024 | 07:09 | Unicorn AIM VCT | 35 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 19/4/2024 09:20 by Unicorn Aim Vct Daily Update Unicorn Aim Vct Plc is listed in the Investors, Nec sector of the London Stock Exchange with ticker UAV. The last closing price for Unicorn Aim Vct was 91.50p.Unicorn Aim Vct currently has 172,876,156 shares in issue. The market capitalisation of Unicorn Aim Vct is £158,181,683. Unicorn Aim Vct has a price to earnings ratio (PE ratio) of -14.95. This morning UAV shares opened at 91.50p |
Posted at 13/2/2024 11:13 by toffeeman Hi BagpussMust stop meeting like this UAV SCE AGL! Seriously though I am not a big earner but have bought UAV in the past to get the 30% tax rebate as I was at the LTA limit in my SIPP. Now however any spare dosh will go into my SIPP for a 40% rebate. |
Posted at 09/2/2024 14:56 by topvest Well I have subscribed to the offer today. I phoned-up to check following yesterday's surprise RNS and they are already £3m through the over-allotment facility. The offer only opened on the 8th...i.e. yesterday. It's very surprising that the share price is where it is, with this much demand. The whole offer may well be fully subscribed in a couple of days! It really does beg the question whether you should hold these VCT investments at bid or NAV in your portfolio. |
Posted at 18/7/2022 09:16 by gbcol It’s 3p & 32p.“Following the sale of Interactive the Board has decided to distribute the entire realised gain by way of a Special Dividend of 32.0 pence per share alongside the interim dividend of 3.0 pence per share. This interim dividend and the special interim dividend will be paid on 11 August 2022 to Shareholders on the register on 15 July 2022. The shares will be quoted ex-dividend on 14 July 2022.” |
Posted at 17/3/2022 14:12 by toffeeman Just bought some of the new issue and with VCT relief my entry price is 138. Now need to leave it alone for 5 years :) |
Posted at 08/12/2021 17:11 by sphere25 This is topical:" Largest Detractors Avacta Group (-GBP1.6 million) is a clinical stage biopharmaceutical specialist and a developer of diagnostics tools based on innovative and proprietary Affimer(R) and pre|CISION(TM) platforms. At the end of September, Avacta released interim results, which confirmed that the business continues to struggle to achieve widespread commercial adoption of its high quality Lateral Flow Tests. Financial results were therefore below original expectations and Avacta's share price has been under considerable pressure as a result. Omega Diagnostics (-GBP1.2 million) is a business focused on providing specialist products to immunoassay, in-vitro diagnostics (IVD) market within the Health & Wellbeing sector. During the year, Omega released results for its financial year ended 31 March 2021. Because of the severe disruption caused by the pandemic, revenues did not grow as quickly as originally anticipated and the share price has suffered accordingly. Abingdon Health (-GBP1.1 million) is a developer and manufacturer of high-quality rapid lateral flow tests. Unfortunately, throughout the year under review, Abingdon has been embroiled in a commercial dispute with the Department of Health and Social Care (DHSC), which translated into significantly lower than expected demand for its AbC-19 rapid antibody testing product. In addition, the DHSC continues to withhold payments due to Abingdon that amount to GBP6.7 million. This dispute remains unresolved, despite Abingdon's insistence that the contract was delivered to the DHSC on time, on budget and in full. As a result, Abingdon has failed to meet growth expectations in the twelve months since its initial listing on the FTSE AIM All-Share Index. Genedrive (-GBP0.9 million) is a molecular diagnostics company that develops and commercialises low cost, rapid, versatile, and simple to use testing platforms for the diagnosis of infectious diseases. In its half yearly report, covering the six months to 31 December 2020, Genedrive was only able to generate nominal revenues as Covid-19 headwinds continued to impact its commercial operations. In September 2021, Genedrive raised GBP6 million in additional capital in order to fund the launch of a point-of-care (POC) antibiotic induced hearing loss (AIHL) test and complete the development of its molecular Covid-19 test. " Should be interesting to see how they all fare next year! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
